期刊文献+

丁酸钠联合顺铂对卵巢透明细胞癌ES-2细胞活性及增殖的影响 被引量:1

Effect of sodium butyrate combined with cisplatin on cell viability and proliferation of ovarian clear cell carcinoma ES-2 cells
下载PDF
导出
摘要 目的观察丁酸钠联合顺铂对卵巢透明细胞癌ES-2细胞活性及增殖的影响。方法将对数生长期的卵巢透明细胞癌ES-2细胞随机分为观察组和对照组。观察组分别加入1、2、4、6 mmol/L的丁酸钠和5μg/m L顺铂,对照组分别加入与观察组相同浓度的丁酸钠。采用MMT法检测两组细胞活性,Western blotting法检测两组凋亡蛋白(c-PAPP、c-Caspase-3)和增殖蛋白(ERK、p-ERK)相对表达量。结果观察组加入1、2、4、6 mmol/L丁酸钠和顺铂细胞活性分别为51%±3%、39%±2%、22%±2%、11%±1%,多组间及组内两两比较,P均<0.05;对照组加入1、2、4、6 mmol/L丁酸钠细胞活性分别为88%±4%、76%±3%、69%±2%、54%±2%,多组间及组内两两比较,P均<0.05;两组加入相同浓度丁酸钠细胞活性比较,P均<0.05。随着丁酸钠浓度增加,两组凋亡蛋白cPAPP、c-Caspase-3相对表达量逐渐升高,增殖蛋白ERK、p-ERK相对表达量逐渐降低。与对照组同浓度丁酸钠比较,观察组1、2、4、6 mmol/L丁酸钠和顺铂c-PAPP、c-Caspase-3蛋白表达均升高,1、6 mmol/L丁酸钠和顺铂ERK、pERK蛋白表达均降低;两组比较,P均<0.05。结论丁酸钠联合顺铂可降低卵巢透明细胞癌ES-2细胞活性,抑制其增殖、促进其凋亡;丁酸钠浓度越高,上述作用越明显。 Objective To observe the effect of sodium butyrate combined with cisplatin on cell viability and proliferation of ovarian clear cell carcinoma ES-2 cells. Methods The ovarian clear cell carcinoma ES-2 cells in the logarithmic phase were randomly divided into the observation groups and control groups. The observation groups were added 1,2,4and 6 mmol / L sodium butyrate( Na B) and 5 μg / m L cisplatin. The control groups were added the same concentrations of Na B. The cell activities were detected by MMT,and the relative expression levels of c-PAPP,c-Caspase-3,ERK and pERK were detected by Western blotting. Results The cell viabilities of the observation groups which were treated with 1,2,4,6 mmol / L Na B and 5 μg / m L cisplatin were 51% ± 3%,39% ± 2%,22% ± 2% and 11% ± 1%,respectively;and significant difference was found between groups( all P < 0. 05). The cell viabilities of the control groups were 88% ±4%,76% ± 3%,69% ± 2% and 54% ± 2%,respectively; and significant difference was found between groups( all P <0. 05). Meanwhile,significant difference was found in the cell viability between the two groups which were added with the same concentrations of Na B( all P < 0. 05). With the increased concentrations of Na B,the relative expression levels of cPAPP and c-Caspase-3 in the two kinds of groups were gradually increased,and the levels of ERK and p-ERK were significantly decreased. Compared with the control groups,the relative expression levels of c-PAPP and c-Caspase-3 in the observation groups which were added 1,2,4 and 6 mmol / L Na B and 5 μg / m L cisplatin were all increased and the levels of ERK and P-ERK were decreased in the observation groups which were added 1 and 6 mmol / L Na B and 5 μg / m L cisplatin.Significant difference was found between the two kinds of groups( all P < 0. 05). Conclusion Na B combined with cisplatin may decrease the cell viability of ovarian clear cell carcinoma ES-2 cells,inhibit the proliferation and promote the apoptosis. The effect can be stronger with the higher concentrations of Na B.
出处 《山东医药》 CAS 北大核心 2015年第32期17-19,共3页 Shandong Medical Journal
基金 国家自然科学基金青年基金资助项目(81201816) 首都医科大学临床基础合作研究基金资助项目(15JL33) 首都医科大学附属北京友谊医院院启动基金资助项目(yyqdkt2014-12)
关键词 卵巢肿瘤 卵巢透明细胞癌 丁酸钠 顺铂 细胞活性 增殖蛋白 凋亡蛋白 ovarian neoplasms ovarian clear cell carcinoma sodium butyrate cisplatin cell viability proliferin apoptin
  • 相关文献

参考文献10

  • 1K Lakshmaiah,Linu Jacob,S Aparna,D Lokanatha,Smitha Saldanha.Epigenetic therapy of cancer with histone deacetylase inhibitors[J]. Journal of Cancer Research and Therapeutics . 2014 (3)
  • 2Lasse Sommer Kristensen,Helene Myrtue Nielsen,Lise Lotte Hansen.Epigenetics and cancer treatment[J]. European Journal of Pharmacology . 2009 (1)
  • 3H. UTSUNOMIYA,J. AKAHIRA,S. TANNO,T. MORIYA,M. TOYOSHIMA,H. NIIKURA,K. ITO,Y. MORIMURA,Y. WATANABE,N. YAEGASHI.Paclitaxel–platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial[J]. International Journal of Gynecological Cancer . 2006 (1)
  • 4Chih-Ming Ho,Yun-Ju Huang,Tze-Chien Chen,Shih-Hung Huang,Fu-Shing Liu,Chan-Chao Chang Chien,Mu-Hsien Yu,Tsui-Lien Mao,Tao-Yeuan Wang,Chang-Yao Hsieh.Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease[J]. Gynecologic Oncology . 2004 (1)
  • 5Toru Sugiyama,Michiaki Yakushiji,Takashi Nishida,Kimio Ushijima,Naofumi Okura,Junzo Kigawa,Naoki Terakawa.Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer[J]. Cancer Letters . 1998 (2)
  • 6Arnold Nichole Boyer,Arkus Nohea,Gunn Jason,Korc Murray.The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research . 2007
  • 7Minucci S,Pelicci PG.Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer . 2006
  • 8Masashi Takano,Yoshihiro Kikuchi,Kazuya Kudoh.Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY . 2011
  • 9M Takano,Y Kikuchi,N Yaegashi,K Kuzuya,M Ueki,H Tsuda,M Suzuki,J Kigawa,S Takeuchi,H Tsuda,T Moriya,T Sugiyama.Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. British Journal of Cancer . 2006
  • 10Dowdy Sean C,Jiang Shujuan,Zhou X Clare,Hou Xiaonan,Jin Fan,Podratz Karl C,Jiang Shi-Wen.Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Molecular Cancer . 2006

共引文献1

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部